Free tool
Oncology stocks
We cover 42 companies grouped under the Oncology theme. The median market value in the group is $497.59M. Across the group, the median move over the past trading day is +2.46%. 95% of the 42 with a 200-day average trade above it. Price change over the past year runs from −23.7% to +316.7% across the middle 80 percent of the group, with a median of +51.1%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
42 of 319 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| 6MK.DE | Merck & Co., Inc. | 129.28 EUR | +11.62% | +44.70% | +83.96% |
| MRK | Merck & Co., Inc. | $156.45 | +19.65% | +48.06% | +88.17% |
| ONC | BeOne Medicines AG | $376.37 | +15.49% | +21.01% | +21.95% |
| BNTX | BioNTech SE | $114.05 | +25.21% | +17.95% | +8.55% |
| GMAB | Genmab A/S | $34.36 | +19.31% | +7.98% | +41.34% |
| 0J9P.L | Incyte Corporation | $130.13 | +1.97% | +30.41% | +53.55% |
| 0M2N.L | Orion Oyj | 80.50 EUR | +12.46% | +29.29% | +19.68% |
| 0I3Q.L | Corcept Therapeutics Incorporated | $122.59 | −2.12% | +233.46% | +75.99% |
| IDYA | IDEAYA Biosciences, Inc. | $42.48 | +15.53% | +25.49% | +71.91% |
| ZLAB | Zai Lab Limited | $26.17 | +40.40% | +51.01% | −23.10% |
| XNCR | Xencor, Inc. Common Stock | $29.30 | +47.53% | +96.38% | +265.79% |
| ZYME | Zymeworks Inc. | $27.47 | +19.43% | +3.19% | +88.54% |
| INBX | Inhibrx Biosciences, Inc. | $122.72 | +48.84% | +63.54% | +390.10% |
| CGEM | Cullinan Therapeutics, Inc. | $22.95 | +31.67% | +126.78% | +200.39% |
| JANX | Janux Therapeutics, Inc. | $18.68 | +19.97% | +36.85% | −18.82% |
| KURA | Kura Oncology, Inc. | $13.59 | +33.89% | +31.49% | +77.65% |
| 4587.T | PeptiDream Inc. | 1,135.00 JPY | +22.00% | −29.98% | −28.26% |
| NVCT | Nuvectis Pharma, Inc. | $25.89 | +32.50% | +204.23% | +298.92% |
| 4588.T | Oncolys BioPharma Inc. | 4,130.00 JPY | +65.80% | +176.44% | +526.71% |
| 0SZI.L | Corbus Pharmaceuticals Holdings, Inc. | $11.16 | +4.01% | +42.04% | +5.13% |
| PRLD | Prelude Therapeutics Incorporated | $6.59 | +69.41% | +141.39% | +418.90% |
| 0LOV.L | Verastem, Inc. | $7.14 | +3.48% | −1.92% | −21.47% |
| 0XOD.L | UroGen Pharma Ltd. | $46.35 | −1.31% | +105.18% | +136.32% |
| CGEN | Compugen Ltd. | $2.87 | +20.59% | +85.16% | +100.70% |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $11.31 | +24.56% | +43.71% | +14.36% |
| ASRT | Assertio Holdings Inc | $23.50 | 0.00% | +157.11% | +98.31% |
| HBP.TO | Helix BioPharma Corp. | 1.99 CAD | +38.19% | −17.08% | +35.37% |
| 0QXX.L | Molecular Partners AG | 3.51 CHF | +2.33% | +3.54% | +22.73% |
| APLM | Apollomics, Inc. | $26.50 | +47.22% | +37.31% | +318.64% |
| SAR.L | Sareum Holdings plc | 29.00 GBP | +31.82% | +70.59% | +38.10% |
| 4572.T | Carna Biosciences, Inc. | 416.00 JPY | +40.54% | +3.48% | +83.26% |
| HOWL | Werewolf Therapeutics, Inc. | $0.89 | +96.47% | +37.98% | −35.04% |
| 4583.T | Chiome Bioscience Inc. | 85.00 JPY | +25.00% | −20.56% | −36.57% |
| KYNB | Kyntra Bio, Inc. | $8.10 | +14.89% | −11.57% | −23.80% |
| BFRI | Biofrontera Inc. | $1.51 | +43.81% | +108.28% | +63.77% |
| ALTME.PA | TME Pharma N.V. | 0.16 EUR | +147.62% | +126.09% | +48.57% |
| CRTX.L | CRISM Therapeutics Corporation | 11.50 GBP | +21.05% | +15.00% | +9.52% |
| APRE | Aprea Therapeutics, Inc. | $0.95 | +51.98% | +11.36% | −40.63% |
| 0NWK.L | Valerio Therapeutics Société anonyme | 0.82 EUR | +3.03% | +393.94% | +1214.52% |
| XBIO | Xenetic Biosciences, Inc. | $3.82 | +52.80% | +77.67% | +33.57% |
| CURX | Curanex Pharmaceuticals Inc | $4.75 | +2495.63% | +1190.76% | +18.16% |
| APM | Aptorum Group Ltd | $8.41 | −6.45% | +685.98% | +260.94% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.